SharePoint
previous slide

Loading ...

Loading ...
next slide
Dr. Jeffrey Heier

Active Studies and Enrolling Patients:

Age-Related Macular Degeneration (AMD)

 Neovascular AMD- DS7080-A-U101 - Phase 1 Dose Escalation And Expansion Study of DS-7080a in Patients with Neovascular Age- Related Macular Degeneration https://clinicaltrials.gov/ct2/show/NCT02530918

Neovascular AMD-RGX-314 - Phase 1 study of RGX-314, a recombinant adeno-associated virus (AAV) gene therapy vector carrying a coding sequence for a soluble anti-VEGF protein. The long-term, stable delivery of this therapeutic protein following a 1 time gene therapy treatment for nAMD could potentially reduce the treatment burden of currently available therapies while maintaining vision with a favorable benefit:risk profile.https://clinicaltrials.gov/ct2/show/NCT03066258

Geographic Atrophy - HMR1001 - This study will evaluate the safety after a single injection of AAVCAGsCD59 administered in an office setting for patients whose enrolled eye has advanced dry AMD with geographic atrophy. The initial study is 26 weeks followed by an additional 18-month safety evaluation.https://clinicaltrials.gov/ct2/show/NCT03144999


 

Diabetic Eye Disease 

Retinal Vein Occlusion - TLC99A2002 - A Phase IIa Trial of TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO): A Double-masked, Randomized Trial to Evaluate Efficacy and Tolerability.https://clinicaltrials.gov/ct2/show/NCT03093701


 

Active Studies No Longer Enrolling Patients:

Age-Related Macular Degeneration 

Neovascular AMD - PRO-CON VGFTe-AMD-1507- A Prospective, Single-Blind, Randomized Study to Evaluate Intravitreal Aflibercept Injection (IAI) versus Sham as PROphylaxis against CONversion to Neovascular Age-Related Macular Degeneration (AMD) in High-Risk Eyes https://clinicaltrials.gov/ct2/show/NCT02462889​

Neovascular AMD - SF0166-C-002 - A Phase I/II Randomized, Controlled, Double-Masked, Multicenter Clinical Trial Designed to Evaluate the Safety and Exploratory Efficacy of SF0166 Topical Ophthalmic Solution in the Treatment of Neovascular Age-Related Macular Degeneration (AMD)​ https://clinicaltrials.gov/ct2/show/NCT02914639

Neovascular AMD - ONYX – REGN910-3-AMD-1517 – A Randomized, Double Masked, Active Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients with Neovascular Age Related Macular Degeneration https://clinicaltrials.gov/ct2/show/NCT02713204

Neovascular AMD - APEX - A Randomized, Double-Masked, Placebo-Controlled, Dose-Finding, Non-Inferiority Study of X-82 Plus PRN Eylea® Compared to PRN Eylea® Monotherapy in Neovascular AMD https://clinicaltrials.gov/ct2/show/NCT02348359

Noevascular AMD - A Phase 1, Open-Label, Multi-Center, Dose-Escalating, Safety and Tolerability Study of a Single intravitreal Injection of AAV2-sFLT01 in Patients with Neovascular AMD https://clinicaltrials.gov/ct2/show/NCT01024998

Neovascular AMD - CAPELLA - R2176-3-AMD-1417- A Phase 2, Double-Masked, Randomized, Controlled, Multiple-Dose, Regimen-Ranging Study of the Efficacy and Safety of Intravitreal REGN2176-3 in Patients with Neovascular Age-Related Macular Degeneration https://clinicaltrials.gov/ct2/show/NCT02503332​ 

AMD - CHROMA GX29176 - A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study To Assess The Efficacy And Safety Of Lampalizumab Administered Intravitreally To Patients With Geographic Atrophy Secondary To Age‑Related Macular Degeneration https://clinicaltrials.gov/ct2/show/NCT02247479

AMD - FILLY - POT-CP121614- A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study of Safety, Tolerability and Evidence of Activity of Intravitreal APL-2 Therapy in Patients Geographic Atrophy (GA) https://clinicaltrials.gov/ct2/show/NCT02503332

Neovascular AMD - OPH1002 – A Phase 3, Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista™ (anti PDGF-B Pegylated Aptamer) Administered in Combination with Lucentis® Compared to Lucentis® Monotherapy in Subjects with Subfoveal Neovascular Age-Related Macular Degeneration https://clinicaltrials.gov/ct2/show/NCT01944839

Diabetic Eye Disease 

Diabetic Retinopathy - PANORAMA – VGFTe-OD-1411 – A Phase III, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients with Moderately Severe to Severe Nonproliferative Diabetic Retinopathy https://clinicaltrials.gov/ct2/show/NCT02718326

Diabetic Macular Edema - SF0166-C-001 - A Phase I/II Randomized, Double-Masked, Multicenter Clinical Trial Designed to Evaluate the Safety and Exploratory Efficacy of SF0166 Topical Ophthalmic Solution in the Treatment of Diabetic Macular Edema (DME) https://clinicaltrials.gov/ct2/show/NCT02914613

RUBY – REGN910-3-DME-1518 – A Randomized, Double Masked, Active Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients with Diabetic Macular Edema https://clinicaltrials.gov/ct2/show/NCT02712008

Chorioretinopathy 

STOMP-CSC – Short-Term Oral Mifepristone for Central Serous Chorioretinopthy: A Placebo-controlled Dose Ranging Study of Mifepristone in the Treatment of CSC https://clinicaltrials.gov/ct2/show/NCT02354170

 

Back to research home page

Find Our Doctors

Request an Appointment
New & Established Patients
* required field   *   *   *   *     *     * Include Preferred Day & Time

Refill a Prescription
Place your order 24/7. OCB utilizes a secure portal called Patient Gateway for prescription refills

Newsletter OCB Summer Newsletter Download ...
View past eNewsletters
Sign Up for OCB's eNewsletter * *
About OCB
OCB Boston
50 Staniford Street, Suite 600
Boston, MA 02114

PH 1.800.635.0489
FAX 1.617.723.7028
Quick Links
Stay Connected
@ OCB All Rights Reserved | Careers | Employee Login
Site Development: Linking Shores Consulting Inc.

Loading ...